<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85697">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01945450</url>
  </required_header>
  <id_info>
    <org_study_id>0186-HMO-CTIL</org_study_id>
    <nct_id>NCT01945450</nct_id>
  </id_info>
  <brief_title>Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth: a Randomized Controlled Trial</brief_title>
  <official_title>Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: There is scarce evidence regarding the necessity of antibiotic prophylaxis in
      manual revision of the uterus after labor in cases of residual placenta.

      Methods: a randomized control trial in which parturients for which the placenta was not
      separated or there is a suspected residual placenta will be divided randomly to two groups:
      (1) Revision of uterus or Manual lysis without antibiotic prophylaxis; (2) Revision of
      uterus or Manual lysis with antibiotic prophylaxis as following: 24 hours coverage with
      Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3. In cases of allergy to
      Penicillin the antibiotic regimen will be: Gentamycin 240 mg*1, Clindamycin 600 mg*3.

      Outcomes: Puerperal fever, endometritis, length of hospitalization after labor, recurrent
      hospitalization in the first 2 weeks after discharge.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Endometritis rate</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Puerperal fever</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Endometritis</condition>
  <arm_group>
    <arm_group_label>Antibiotic prophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic prophylaxis</intervention_name>
    <description>antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3</description>
    <arm_group_label>Antibiotic prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ampicillin</intervention_name>
    <arm_group_label>Antibiotic prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamycin</intervention_name>
    <arm_group_label>Antibiotic prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
    <arm_group_label>Antibiotic prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  suspected retained placenta

        Exclusion Criteria:

          -  Intrapartum fever
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hadas Lamnerg, MD</last_name>
    <phone>: 00 972 2 6777572</phone>
    <email>lhadas@hadassah.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>November 26, 2013</lastchanged_date>
  <firstreceived_date>September 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometritis</mesh_term>
    <mesh_term>Placenta Accreta</mesh_term>
    <mesh_term>Placenta, Retained</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin-2-phosphate</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
